PRKCZ-AS1 promotes the tumorigenesis of lung adenocarcinoma via sponging miR-766-5p to modulate MAPK1.

In this study, the expression of PRKCZ-AS1 in LUAD tissues and cell lines was notably upregulated. Moreover, knockdown of PRKCZ-AS1 inhibited the proliferation and migration, but promoted apoptosis in LUAD cells. Furthermore, miR-766-5p could bind with PRKCZ-AS1. Besides, the expression miR-766-5p was negatively regulated by PRKCZ-AS1 expression in LUAD cells. Furtherly, PRKCZ-AS1 expression positively regulated the expression of MAPK1. Similarly, the expression of MAPK1 was negatively regulated by miR-766-5p expression. Moreover, the binding ability between miR-766-5p and MAPK1 was confirmed. Furthermore, knockdown of MAPK1 partly rescued the miR-766-5p inhibition-mediated promoting effect on proliferation and migration in LUAD cells transfected with PRKCZ-AS1#1. Overall, above results suggested that PRKCZ-AS1 promotes the occurrence of LUAD by sponging miR-766-5p to upregulate MAPK1 expression, which may provide new insights into LUAD treatment. PMID: 31939714 [PubMed - as supplied by publisher]
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research

Related Links:

CONCLUSION: In decision-making between segmentectomy and lobectomy, adequate margins are required for the selection of segmentectomy, the most common of which is LUL trisegmentectomy. Technical challenges can be overcome with adequate training and simulation. Additional research could focus on the identification of factors associated with recurrence. PMID: 32097983 [PubMed - as supplied by publisher]
Source: Surgical Technology International - Category: Surgery Tags: Surg Technol Int Source Type: research
Conclusion: The MSTRG51053.2 lncRNA may function as a ceRNA for miR-432-5p to regulate the DDP resistance in NSCLC. The MGST1, MGST3, GST-ω1, and ABCG2 mRNAs, miR-432-5p and miR-665 miRNAs, and MSTRG51053.2 and PPAN lncRNAs can serve as potential DDP drug targets to reverse DDP resistance in NSCLC.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: We strictly determined prognostic genes of NSCLC, which would contribute to its carcinogenesis investigation and therapeutic methods improvement. PMID: 32083573 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Lung adenocarcinoma (LUAD) is a common histological type of non-small cell lung cancer (NSCLC), accounting for nearly 40% of all lung cancers [1]. Current research has identified several LUAD-specific oncoproteins with differential expression of wildtype or mutant forms, which includes the REarranged during Transfection (RET) receptor tyrosine kinase (RTK). The expression and activation of RET has been implicated in multiple cancers, including lung [2,3]. RET is expressed at low levels in normal lung tissues, however RET gene rearrangements give rise to chimeric proteins with constitutive kinase activity that drive tumouri...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractAnti ‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely cle ar. Therefore, to identify reliable biomarkers as predictors of clinical response and resistance to anti‐PD‐1/PD‐L1 therapies have become increasingly important. Here, we report a case of a patient with bone metastatic NSCLC, who achieved a pathologic complete response after preoperative pembr olizumab treatm...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Despite the increase of therapeutic options available in clinical setting, non-small cell lung cancer (NSCLC) still remains the leading cause of cancer-related death in both sexes worldwide, representing over 85% of all lung cancers.[1] The clinical knowledge of the epidermal growth factor receptor (EGFR) molecular status, emerging over a decade ago, has led to a dramatic shift in the treatment paradigm of metastatic NSCLC. The prevalence of EGFR mutations ranges from 10% to 15% in Caucasian patients [2] and up to 50% in East-Asian patients, [3] mainly but not only with adenocarcinoma histology, female gender and quite pec...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: The miR-1323 promoted LUAD migration through inhibiting Cbl-b expression. High miR-1323 expression predicted poor prognosis in LUAD patients.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Cancer diagnosis should always be considered in patients with unprovoked thrombosis and, if NSCLC is diagnosed, genetic alterations should be always sought after. A possible relation between venous thromboembolism and oncogenic drivers, particularly for ALK translocations, has been hypothesized. Similarly to ALK-positive NSCLC, ROS1 rearranged disease has been associated with an increased thromboembolic risk. Further studies are needed to better evaluate this relation and to evaluate the potential benefit of a prophylactic anticoagulating treatment in this subset of patients. PMID: 32066344 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Abstract The purpose of the present study was to evaluate the clinical profiles and treatment outcomes of patients with lung cancer admitted to the Medical Psychiatric Unit (MPU), which is built for patients with physical and severe psychiatric disorders. All medical records of patients with lung cancer admitted to the MPU of Tachikawa hospital were reviewed. The clinical outcomes of these patients were retrospectively evaluated between January 2010 and December 2016. A total of 24 patients in the MPU were histologically or cytologically diagnosed with primary lung cancer. Of these, 20 patients had schizophrenia, ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Advanced non-small cell lung cancer (NSCLC) is a devastating disease that is incurable and associated with poor outcomes worldwide [1]. Targeted therapies with predictive biomarkers have changed the health care strategy for metastatic NSCLC patients [2]. An anaplastic lymphoma kinase (ALK) gene rearrangement is a distinct driving mutation that occurs in as many as 8% of patients with NSCLC. Of note, different fusion partners can influence the response to ALK inhibition in patients with NSCLC [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Adenocarcinoma | Biology | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study